NCT00002649View on ClinicalTrials.gov

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

May 31, 1995

Primary Completion Date

November 30, 2006

Conditions
Recurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular Lymphoma
Interventions
BIOLOGICAL

aldesleukin

Given IV

BIOLOGICAL

filgrastim

Given SC or IV

DRUG

cyclophosphamide

Given IV

DRUG

etoposide

Given IV

RADIATION

radiation therapy

Undergo radiation therapy

PROCEDURE

peripheral blood stem cell transplantation

Undergo autologous peripheral blood stem cell transplant

PROCEDURE

bone marrow ablation with stem cell support

Undergo bone marrow ablation with stem cell support

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00002649 - Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter